Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates

Sohee Jeon, Won Ki LeeDepartment of Ophthalmology, Seoul St Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, KoreaBackground: We evaluated the efficacy of intravitreal bevacizumab on diabetic macular edema with subfoveal and perifoveal hard exudates.Materials...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jeon S, Lee WK
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/c1bafa089a844ce8b05e84483ea41455
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c1bafa089a844ce8b05e84483ea41455
record_format	dspace
spelling	oai:doaj.org-article:c1bafa089a844ce8b05e84483ea414552021-12-02T09:24:24ZEffect of intravitreal bevacizumab on diabetic macular edema with hard exudates1177-5483https://doaj.org/article/c1bafa089a844ce8b05e84483ea414552014-08-01T00:00:00Zhttp://www.dovepress.com/effect-of-intravitreal-bevacizumab-on-diabetic-macular-edema-with-hard-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483 Sohee Jeon, Won Ki LeeDepartment of Ophthalmology, Seoul St Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, KoreaBackground: We evaluated the efficacy of intravitreal bevacizumab on diabetic macular edema with subfoveal and perifoveal hard exudates.Materials and methods: Eleven eyes (11 patients) exhibiting diabetic macular edema with subfoveal and perifoveal hard exudates were included in this prospective, nonrandomized interventional pilot study. All patients were treated with monthly scheduled intravitreal bevacizumab injections for 6 months. Changes in the Early Treatment Diabetic Retinopathy Study best corrected visual acuity, amount of hard exudates on fundus photography, and macular edema detected by central subfield thickness on spectral domain optical coherence tomography after six serial injections, were assessed. The amount of hard exudates at each visit was evaluated as pixels in fundus photography, using an Adobe Photoshop program. Results: Ten of 11 patients completed follow-up. The mean Early Treatment Diabetic Retinopathy Study best corrected visual acuity was 59.9±5.7 letters (Snellen equivalent, 20/63) at baseline evaluation. The best corrected visual acuity exhibited no significant difference at month 6 compared with at baseline (57.9±6.0 letters or 20/70 at month 6; P=0.085). At month 6, mean central subfield thickness decreased from 370.4±56.5 to 334.6±65.0 µm (P=0.009). The mean amount of hard exudates increased from 4467.1±2736.1 to 6592.4±2498.3 pixels at month 6 (P=0.022). No serious adverse events occurred.Conclusion: Continuous intravitreal bevacizumab was found to have no benefit in visual acuity and amount of hard exudates, despite the improvement of macular edema at 6 months. Keywords: bevacizumab, diabetic macular edema, hard exudatesJeon SLee WKDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2014, Iss default, Pp 1479-1486 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Jeon S Lee WK Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates
description	Sohee Jeon, Won Ki LeeDepartment of Ophthalmology, Seoul St Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, KoreaBackground: We evaluated the efficacy of intravitreal bevacizumab on diabetic macular edema with subfoveal and perifoveal hard exudates.Materials and methods: Eleven eyes (11 patients) exhibiting diabetic macular edema with subfoveal and perifoveal hard exudates were included in this prospective, nonrandomized interventional pilot study. All patients were treated with monthly scheduled intravitreal bevacizumab injections for 6 months. Changes in the Early Treatment Diabetic Retinopathy Study best corrected visual acuity, amount of hard exudates on fundus photography, and macular edema detected by central subfield thickness on spectral domain optical coherence tomography after six serial injections, were assessed. The amount of hard exudates at each visit was evaluated as pixels in fundus photography, using an Adobe Photoshop program. Results: Ten of 11 patients completed follow-up. The mean Early Treatment Diabetic Retinopathy Study best corrected visual acuity was 59.9±5.7 letters (Snellen equivalent, 20/63) at baseline evaluation. The best corrected visual acuity exhibited no significant difference at month 6 compared with at baseline (57.9±6.0 letters or 20/70 at month 6; P=0.085). At month 6, mean central subfield thickness decreased from 370.4±56.5 to 334.6±65.0 µm (P=0.009). The mean amount of hard exudates increased from 4467.1±2736.1 to 6592.4±2498.3 pixels at month 6 (P=0.022). No serious adverse events occurred.Conclusion: Continuous intravitreal bevacizumab was found to have no benefit in visual acuity and amount of hard exudates, despite the improvement of macular edema at 6 months. Keywords: bevacizumab, diabetic macular edema, hard exudates
format	article
author	Jeon S Lee WK
author_facet	Jeon S Lee WK
author_sort	Jeon S
title	Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates
title_short	Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates
title_full	Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates
title_fullStr	Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates
title_full_unstemmed	Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates
title_sort	effect of intravitreal bevacizumab on diabetic macular edema with hard exudates
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/c1bafa089a844ce8b05e84483ea41455
work_keys_str_mv	AT jeons effectofintravitrealbevacizumabondiabeticmacularedemawithhardexudates AT leewk effectofintravitrealbevacizumabondiabeticmacularedemawithhardexudates
_version_	1718398146394980352

Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates

Ejemplares similares